Phase II Umbrella Study Directed by Next Generation Sequencing
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This phase II, umbrella trial study directed by next generation sequencing (NGS) works in
Chinese patients with advanced stage NSCLC who never received any anti-tumor treatment. The
purpose of this study is to evaluate efficacy of targeted therapies or immunotherapy to NSCLC
patients whose tumor harbors a genomic variant known to be a drug target or to predict
sensitivity to a drug.